This disclosure relates to a surgical heart valve for heart valve replacement and, more particularly, to surgical heart valves having indicators visible from outside the body post-implant.
The heart is a hollow muscular organ having four pumping chambers and four heart valves: aortic, mitral (or bicuspid), tricuspid, and pulmonary. Heart valves are comprised of a dense fibrous ring known as the annulus, and leaflets or cusps attached to the annulus.
Heart valve disease is a widespread condition in which one or more of the valves of the heart fails to function properly. Diseased heart valves may be categorized as either stenotic, wherein the valve does not open sufficiently to allow adequate forward flow of blood through the valve, and/or incompetent, wherein the valve does not close completely, causing excessive backward flow of blood through the valve when the valve is closed. Valve disease can be severely debilitating and even fatal if left untreated. Various surgical techniques may be used to replace or repair a diseased or damaged valve. In a traditional valve replacement operation, the damaged leaflets are typically excised and the annulus sculpted to receive a replacement prosthetic valve.
A surgical prosthetic heart valve typically comprises a support structure (such as a frame, ring and/or stent) with a valve assembly deployed therein. The support structure is often rigid, and can be formed of various biocompatible materials, including metals, plastics, ceramics, etc. Two primary types of heart valve replacements or prostheses are known. One is a mechanical-type heart valve that uses a ball and cage arrangement or a pivoting mechanical closure supported by a base structure to provide unidirectional blood flow, such as shown in U.S. Pat. No. 6,143,025 to Stobie, et al. and U.S. Pat. No. 6,719,790 to Brendzel, et al., the entire disclosures of which are hereby expressly incorporated by reference. The other is a tissue-type or “bioprosthetic” valve having flexible leaflets supported by a base structure and projecting into the flow stream that function much like those of a natural human heart valve and imitate their natural flexing action to coapt against each other and ensure one-way blood flow.
In tissue-type valves, a whole xenograft valve (e.g., porcine) or a plurality of xenograft leaflets (e.g., bovine pericardium) can provide fluid occluding surfaces. Synthetic leaflets have been proposed, and thus the term “flexible leaflet valve” refers to both natural and artificial “tissue-type” valves. In a typical tissue-type valve, two or more flexible leaflets are mounted within a peripheral support structure that usually includes posts or commissures extending in the outflow direction to mimic natural fibrous commissures in the native annulus. The metallic or polymeric “support frame,” sometimes called a “wireform” or “stent,” has a plurality (typically three) of large radius cusps supporting the cusp region of the flexible leaflets (e.g., either a whole xenograft valve or three separate leaflets). The ends of each pair of adjacent cusps converge somewhat asymptotically to form upstanding commissures that terminate in tips, each extending in the opposite direction as the arcuate cusps and having a relatively smaller radius. Components of the valve are usually assembled with one or more biocompatible fabric (e.g., Dacron® polyethylene terephthalate (PET)) coverings, and a fabric-covered sewing ring is provided on the inflow end of the peripheral support structure.
One example of the construction of a flexible leaflet valve is seen in U.S. Pat. No. 6,585,766 to Huynh, et al. (issued Jul. 1, 2003), in which the exploded view of
Sometimes the need for complete valve replacement may arise after a patient has already had an earlier valve replacement for the same valve. For example, a prosthetic heart valve that was successfully implanted to replace a native valve may itself suffer damage and/or wear and tear many years after initially being implanted. Implanting the prosthetic heart valve directly within a previously-implanted prosthetic heart valve may be impractical, in part because the new prosthetic heart valve (including the support structure and valve assembly) will have to reside within the annulus of the previously-implanted heart valve, and traditional prosthetic heart valves may not be configured to easily receive such a valve-within-a-valve implantation in a manner which provides secure seating for the new valve while also having a large enough annulus within the new valve to support proper blood flow therethrough.
Some attention has been paid to the problem of implanting a new valve within an old valve. In particular, the following disclose various solutions for valve-in-valve systems: U.S. Patent Application Publication No. 2010/0076548 A1 to Konno, filed Sep. 19, 2008; and U.S. Pat. No. 8,613,765 to Bonhoeffer, filed Jul. 7, 2011.
Despite certain advances in the valve-in-valve area, there remains a need to quickly identify physical characteristics of a previously implanted heart valve, including whether a previously implanted surgical valve is suitable for a valve-in-valve procedure.
The present application solves a number of problems related to identification of prosthetic heart valves post-implant. The heart valves have an indicator thereon visible from outside the body by an external imager, post-implant. The indicator communicates the size or orifice diameter of the surgical valve, and may also show that the valve has the capacity for post-implant expansion. It can also communicate other information, such as any combination of the manufacturer and/or model of the valve, the type of bioprosthetic tissue or other material used to make the leaflets, and the valve's compatibility with other types of valves. The indicator may be an alphanumeric symbol and/or other symbol or symbols that represent, for example, the valve size number and/or other characteristic.
The present application discloses specific modifications to existing surgical valves that enable manufacturers to rapidly produce a valve which accommodates valve-in-valve (ViV) procedures. Specifically, some embodiments disclosed in the present application include retrofitting or modifying components within existing types of surgical valves to enable post-implant expansion.
In one embodiment of the present application, a prosthetic heart valve comprises an internal support frame defining a flow orifice therethrough and wherein the internal support frame is adapted for post-implant expansion. A plurality of flexible leaflets attaches to the support frame so as to extend across the flow orifice and come together within the orifice and provide one-way flow therethrough. The prosthetic heart valve further includes a valve-type indicator that provides information about a characteristic of the heart valve and is visible using an external imager. The valve-type indicator may signify the capability of the support frame for post-implant expansion of the orifice.
The prosthetic heart valve preferably has a labeled valve size, and the valve-type indicator comprises a valve-size indicator that denotes the labeled valve size and is visible or readable using an external imager. For example, the valve-size indicator comprises a numerical value that equals the labeled valve size in millimeters. In one embodiment, the internal support frame comprises a structural component that shows up as a positive image on the external imager, and the valve-type indicator is formed by one or more voids integrated into the structural component that show up as negative images on the external imager. For instance, the structural component of the internal support frame may be a generally tubular band that is adapted for post-implant expansion. In some embodiments, the valve-type indicator is integrated into a structural component to provide a positive image, for example as part of a band, stent, and/or wireform.
In another embodiment, the valve-type indicator comprises an indicator element that shows up as a positive image on the external imager mounted to a structural component of the prosthetic heart valve that is not clearly visible to the external imager so that the valve-size indicator shows in contrast to the structural component on the external imager. For example, the structural component comprises a soft sealing ring surrounding an inflow end of the heart valve, and the indicator element is mounted to the sealing ring.
In one aspect, the prosthetic heart valve further includes an expandable tubular frame attached to an inflow end of the internal support frame on which the valve-size indicator is located. In such a configuration, the expandable tubular frame may have a series of circumferential and axial struts, wherein an upper strut is shaped with peaks and valleys around its periphery, and the valve-type indicator is integrated into the frame as a tag below the upper strut and along one of the axial struts. The expandable tubular frame is desirably metallic and is formed by laser cutting with the tag being the same material as the frame and formed during the laser cutting process.
In another embodiment, a prosthetic heart valve disclosed herein comprises an internal support frame defining a flow orifice therethrough, and a plurality of cusps that curve toward the inflow end separated by commissures. The support frame comprising an annular element disposed at an inflow end of the support frame that undulates so as to have peaks and valleys, with the peaks corresponding to the commissures of the support frame. A plurality of flexible leaflets attach to the support frame and extend across the flow orifice so as to come together within the orifice and ensure one-way flow therethrough, each of the leaflets attaching at a peripheral edge along the cusps and commissures of the support frame. An indicator is located on the annular element, for example, on at least one of the peaks or on at least one of the valleys of the annular element, that denotes a valve type and is visible or readable using an external imager.
In one form, the annular element includes a single expandable segment formed by overlapping free ends located at one of the cusps of the support frame. Preferably, there are identical indicators provided on each of the peaks in the middle of each valley around the annular element. The prosthetic heart valve has a labeled valve size, and the valve-type indicator may comprise a numerical value that equals, or a non-numeric symbol representative of, the labeled valve size in millimeters. The annular element desirably comprises a generally tubular metallic band that shows up as a positive image on the external imager, and the valve-type indicator is formed by one or more voids integrated into the band which show up as negative or positive images on the external imager.
The heart valve may further include an expandable tubular frame attached to an inflow end of the internal support frame on which a second valve-type indicator is located. The expandable tubular frame may comprise a series of circumferential and axial struts, wherein an upper strut is shaped with peaks and valleys around its periphery, and the valve-type indicator is integrated into the frame as a tag below the upper strut and along one of the axial struts.
Some embodiments provide a prosthetic heart valve, comprising: an internal support frame defining a flow orifice therethrough, the internal support frame is adapted for post-implant expansion; a plurality of flexible leaflets attached to the support frame and extending across the flow orifice and coming together within the orifice to define one-way flow therethrough; and a valve-type indicator that provides information about a characteristic of the heart valve, the valve-type indicator readable using an external imager.
Some embodiments provide a prosthetic heart valve, comprising: an internal support frame defining a flow orifice therethrough, the internal support frame defining a plurality of cusps that curve toward the inflow end separated by commissures, the support frame comprising an annular element disposed at an inflow end of the support frame that undulates so as to have peaks and valleys, with the peaks corresponding to the commissures of the support frame; a plurality of flexible leaflets attached to the support frame and extending across the flow orifice and coming together within the orifice to ensure one-way flow therethrough, each of the leaflets attaching at a peripheral edge along the cusps and commissures of the support frame; and an indicator comprising at least one feature in annular element at least a portion of the indicator having a radiopacity different from the radiopacity of the annular element, the indicator indicating a valve type and visible using an external imager. At least a portion of the annular element can be radiopaque, with the indicator including at least one opening extending through the at least one radiopaque portion of the annular element.
Some embodiments provide a method for replacing a prosthetic valve in need thereof, the method comprising: reading a valve-type indicator of a first prosthetic valve, selecting a second prosthetic valve based on the information read, and deploying the second prosthetic valve in the first prosthetic valve. Optionally, the method includes expanding a diameter of the first prosthetic valve prior to, contemporaneously with, or simultaneously with deploying the second prosthetic valve.
Other features and advantages of the present invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings which illustrate, by way of example, the principles of the invention.
The prosthetic heart valves described herein each include an internal (meaning incorporated into the valve itself as opposed to being a supplemental element) stent or frame that is generally tubular in shape and defines a flow orifice area through which blood flows from an inflow end to an outflow end. Alternatively, the shape of the internal stent can be oval, elliptical, irregular, or any other desired shape. The valves preferably include flexible leaflets that selectively allow for fluid flow therethrough. Thus, the flow orifice area is alternatively open and closed via movement of leaflets. The heart valves may also include an outer or peripheral sewing or sealing ring formed of soft, suture-permeable material, which is typically used as an anchor to secure the valve to a native annulus, but can also be primarily for sealing against paravalvular leaking.
As referred to herein, the prosthetic heart valves used in accordance with the devices and methods of the invention may include a wide variety of different configurations, such as a prosthetic heart valve having one or more bioprosthetic tissue leaflets (e.g., bovine or porcine), a synthetic heart valve having polymeric leaflets, and in general any that are configured for replacing a native or previously implanted prosthetic heart valve. The prosthetic heart valves described herein are typically used for replacement of aortic, mitral, tricuspid, or pulmonic valves, but may also be used as a venous valve. These replacement prosthetic heart valves can also be employed to functionally replace stentless bioprosthetic heart valves.
In a preferred embodiment, internal valve stents or support frames disclosed herein have “expandable segments” that enable post-implant expansion. This can occur from the expandable segment rupturing, plastically stretching, and/or elastically elongating. Thus, an “expandable segment” means a location on the stent that enables it to enlarge in diameter, such as when a balloon is inflated within the stent. Examples include weak points which can rupture, thinned areas that rupture or stretch, accordion-like structures that elongate elastically or plastically, breaks in the stent that are held together with a breakable member such as a suture, weak link, or spot weld, and various other means. The term, “expandable segment” thus encompasses each and every one of these alternatives. For example, U.S. patent application Ser. No. 14/136,318, filed Dec. 20, 2013, and U.S. Patent Application Publication Nos. 2010/0076548 A1 and 2011/0264207 A1 disclose various embodiments of expandable valves, the contents of which are expressly incorporated herein by reference.
In the exemplary Perimount® valves, the outer band 40 is metallic (such as Elgiloy® Co—Cr—Ni alloy) and is formed from an elongated strip of metal curved to the generally circular shape and having free ends that are welded together. In contrast, the inner band 42 is formed of a biocompatible polymer such as polyester (PET) or Delrin® polyacetal that may be molded, and also may be formed as a strip, circularized, and welded or bonded closed (not shown). Both the outer and inner bands 40, 42 typically feature a series of through holes that register with each other so that the assembly can be sewn together. The wireform 26 and the commissure posts 44 of the inner band 42 provide flexibility to the commissures of the valve, which reduces stress on the bioprosthetic material of the leaflets 24. The inflow end or base of the valve 20 surrounded by the sewing ring 36, however, comprises the relatively rigid circular portions of the structural stent 28. The combination of the metallic outer and plastic inner bands 40, 42 presents a relatively dimensionally stable circumferential base to the valve, which is beneficial for typical uses. These same characteristics of the structural stent 28 that provide good stability for the surgical valve resist post-implant expansion of the valve, however. Consequently, the structural stent 28 may be modified to facilitate expansion thereof for use in a valve-in-valve procedure.
The ability of a previously implanted prosthetic heart valve to expand is not always known. Indeed, the procedure is relatively new, and therefore most implanted valves have not been designed for radial expansion. Moreover, expandable valves that are now more frequently implanted may not be easily identified by a surgical team considering a valve-in-valve procedure. Although notes of each patient's surgery are taken at the time of each procedure, poor record-keeping, a lack of communication between doctors and hospitals, patient relocations to different states and even countries, the presence of an emergency, and other factors may make those records unavailable to a subsequent surgical team years later. Indeed, even information as seemingly straightforward as the size of the previously implanted prosthetic heart valve may not be readily available, and imaging from outside the body may not provide a precise determination of the valve size.
Consequently, the present application provides various solutions for easily identifying surgical heart valves in terms of size and type. In a preferred embodiment, at least the size of the heart valve is indicated on a component thereof in a manner that is visible from outside the body, post-implant. As used herein, “visible” includes the senses of “readable,” “visualizable,” “detectable,” and “interpretable.” For instance,
Components within the prosthetic heart valves can also be coded so that they indicate whether the valve is expandable or not. It should be understood, however, that the valve-size indicators may also be used for non-expandable valves, as well as those that are capable of post-implant expansion. Any subsequent valve surgery benefits from knowledge of the size of the previously-implanted heart valve. Additional information on the previously-implanted valve, such as the manufacturer and/or model of the valve, and the valve's compatibility with other types of valves is also beneficial and can be encoded on the prosthetic heart valve as well.
The term “imager” for use from outside the body (“external imager”) to detect the indicators includes any device capable of visualizing discrete elements inside the body from the outside, in general any device used in the fields of radiology that can produce such images. These fields include X-ray imaging or fluoroscopy which sees reflected X-rays, magnetic resonance imaging, medical ultrasonography or ultrasound, and nuclear medicine functional imaging techniques such as positron emission tomography. The term “imager” also includes devices or systems that include at least one component that is disposed within a patient's body, for example, an ultrasound emitter.
As mentioned, various alternatives of the valve-size indicators are described herein.
The outer band 40 comprises two overlapping free ends 66 held together by a frictional sleeve 68. This is one possible embodiment permitting expansion of the band 40, and thus the entire valve 20. More detail about this arrangement will be provided below. It should be noted however that the inner band 42 (
The term “voids” refers to numbers, holes, geometric or other symbols formed or cut into the radiopaque support bands described herein, or other radiopaque internal elements of a valve support frame. By cutting the void into an otherwise solid element, the indicator will show up as a negative image when visualized through an external imager. For example, the numeric characters “21” shown in the band 40 of
In
Finally, in
It should be noted here that the valve-type indicator, described herein as identifying an expandable valve, can also be used to provide further valve type information. For instance, the indicator may show what type of bioprosthetic tissue or other material is used in the valve, the valve manufacturer and/or model, the valve's compatibility with other valves, etc. Consequently, the term “valve type” refers to any valve-specific information, not just whether the valve is capable of expansion.
The upper valve portion 226 desirably includes a peripheral internal support frame, partially shown in the cutaway of
In a preferred embodiment, the support frame is defined partly by an undulating wireform 240 that defines the commissure posts 230 and extends around a generally tubular area and a structural stent 242 that may comprise annular bands; the parts similar to those shown at 62 and 64 in
The prosthetic heart valve 220 is considered a “hybrid” type in that it includes the upper valve portion 226 constructed similar to typical surgical valves, with a relatively stable diameter that is not normally intended to be compressed or expanded, while the connected lower frame 222 is expandable to help in anchoring the valve in place. One specific commercial prosthetic heart valve that is constructed in this manner is one which is sold in conjunction with the Edwards Intuity® valve system from Edwards Lifesciences of Irvine, Calif. The Edwards Intuity® valve system comprises a “hybrid” valve incorporating a surgical Perimount®-like valve with a stainless steel lower frame structure. In contrast to a typical Edwards Intuity® valve, however, the valve portion 226 is modified in any of the manners described herein to permit post-implant expansion for use in a valve-in-valve procedure. Further, the heart valve 220 includes a size indicator to facilitate such a procedure.
With specific reference to
The upper row strut 250 includes a plurality of eyeholes 252, evenly spaced apart in the illustrated embodiment, and located just below the top edge thereof that are useful for securing the frame 222 to the fabric of the underside of the valve portion 226, for example, using suture. A series of axial column struts 254 depend downward from the upper row strut 250, and specifically from each of the eyeholes 252, and connect the upper row strut to two lower row struts 256. The lower row struts 256 circumscribe the frame 222 in zig-zag patterns, with an inverted “V” shape between each two adjacent column struts 254. The lower row struts 256 preferably extend horizontally, and the length of the column struts 254 thus varies with the undulating upper row strut 250.
As mentioned above, the lower frame 222 may be plastically expanded, such as by balloon expansion, and may be formed of stainless steel or cobalt-chromium alloy, for example. In a typical Edwards Intuity® valve, the upper row strut 250 is generally ring-like without capacity for expansion. In the illustrated frame 222, on the other hand, a series of spaced notches 260 are provided that permit expansion. That is, circumferential segments of the strut 250 are interrupted by the V-shaped notches 260 which permits a limited amount of expansion, for example, about 3 mm in diameter, to accommodate a supplemental expandable valve to be inserted and expanded therein.
In addition, a number of valve-type indicators 224 are integrated into the frame 222 at locations around its circumference, such as three valve-size indicators. In the illustrated embodiment, the valve-size indicators 224 comprise small plate-like tags inscribed with the numerical valve size in mm, for example 21 mm in the illustrated embodiment. The use of any combination of alphanumeric characters and/or symbols that signify size and/or other features of the valve is contemplated. The frame 222 may be laser cut from a tubular blank, with the plate-like size indicators 224 left connected to one more of the struts. As shown, the size indicators 224 are located just below the peaks 251 of the undulating upper row strut 250, connected between the corresponding eyehole 252 and the descending column strut 254. There are thus three size indicators 224 spaced about 120° apart around the frame 222. The illustrated location beneath the peak 251 provides additional space between the upper row strut 250 and the adjacent lower row strut 256. Further, the frame 222 typically has more real estate in which to place the size indicators 224 than the bands of the valve portion 226. The inscribed or cutout valve size numerals are sufficiently large to be visualized with X-ray, Transesophageal Echocardiogram (TEE), or other imaging technique. In one embodiment, the valve size numerals are from about 1.5 mm to about 2 mm in height, for example, about 1.75 mm.
It should be understood that instead of the numerical valve-size indicators cut into the tags, any of the above-referenced size indicators may also be used in the same place. It is especially useful where the indicators are integrated into existing structures rather than being separate add-ons that require a separate attachment step. This not only reduces assembly time and cost, but also ensures the indicators are located at the ideal location for visualization, without requiring an alignment procedure. For instance, the various indicators disclosed herein are laser cut or stamped into the respective metallic parts, or distinguished by providing reflective coatings and the like on the parts.
Note that there are many variations of the above-described embodiments, including numerous combinations of the various embodiments, all of which are in the scope of the invention. For instance, the various numeric and symbolic indicators of valve size or valve type could be provided as radiopaque additions to the sewing ring, or in general mixed and matched as deemed necessary. Also, a particular support structure could have any combination of the above-discussed expandable portions.
As previously described, the at least one size indicator can be made of any suitable material, e.g., radiopaque or radiopaque impregnated material. The radiopaque material selected for this purpose may be biocompatible. Such materials include stainless steel, tungsten, tantalum, platinum, gold, barium silicate, as well as alloys such as cobalt-chromium (e.g., Elgiloy® alloy) or high-performance nickel alloys (e.g., Hastelloy® alloys).
Various processes exist for forming the radiopaque markers from such materials. In some embodiments, an etching process can be used to create the articles of the markers. This process may be a photo etching process whereby a photo-resistive coating is applied as a mask to a light-sensitive polymer plate. Light is projected onto the plate and the plates are then washed to remove the photo-resistive material that was used as the mask. An additional washing step may then be used to chemically remove the portion of the metal that was exposed to the light. In other embodiments, the photo-resistive coating and the exposed metal can be removed in one washing step. Other similar etching processes may be used as are known to those skilled in the art.
Another mechanism for creating the radiopaque articles for use in the described markers involves punching the articles from a sheet of radiopaque material. For instance, a ribbon of material may be fed into a die set having male and female portions that stamp out the characters. With a punching process, any rough edges and/or burrs generated thereby may need to be removed, polished, or cleaned.
Yet another technique for producing the radiopaque articles involves using a laser cutting technique, as mentioned. Laser cutting can produce very tight tolerances and smooth edges, aiding readability of small radiopaque markers. Some materials, however, may be expensive or difficult to process using this technique. In particular, this technique may be expensive at higher volume production levels.
Still another option for creating the radiopaque articles involves a sintering process. According to this technique, powdered radiopaque material mixed with glue is pressed into a form and baked until all of the glue has been dissipated and the radiopaque particles bind together. This type of process creates a porous structure which may more readily adhere to the molecules of a polymer used during a subsequent molding process, with the degree to which the polymer is received by the pores being dependent upon molecular size of the polymer.
Metal injection molding can also be used to create the radiopaque articles. In this scenario, a radiopaque powder or slurry is injected under pressure into a mold. The powder or slurry is then baked until the radiopaque particles bind one to another. As with sintering, this may produce a relatively more porous radiopaque article.
A prosthetic valve may lose effectiveness or fail for any number of reasons, for example, stenosis, pannus growth, regurgitation, and/or mechanical failure. Under such circumstances, replacement may be desirable. One option is to remove the failing prosthetic valve, for example, surgically, and to implant a new prosthetic valve in its place, Another option is to perform what-is-known as a valve-in-valve procedure in which a new valve is implanted into the failing valve without removal thereof. Where the new valve is a transcatheter valve, the procedure may be performed using minimally invasive procedures that are less traumatic to the patient. Although the failing valve is not actually removed, the procedure is often referred to as a “replacement” because the new prosthetic valve replaces the function of the failing valve.
An embodiment of a method for replacing a first prosthetic valve in need thereof with a second prosthetic valve includes reading a valve-type indicator of the first prosthetic valve, selecting a second prosthetic valve based on the information read, and deploying the second prosthetic valve in the first prosthetic valve. The first prosthetic valve includes any prosthetic valve including a valve-type indicator, including any of the embodiments described herein. The valve-type indicator can be of any type or combination of types described herein, for example, size, expandability, make, model, or any other information desired. The valve-type indicator is read, imaged, or visualized as described above.
Optionally, a diameter of the first prosthetic valve is expanded, for example, either immediately before, contemporaneously with, or simultaneously with the deployment with the second prosthetic valve. In some examples, the first prosthetic valve is expanded mechanically, for example, using a balloon, before the second prosthetic valve is deployed. In other examples, the deployment of second prosthetic valve itself expands the diameter of the first prosthetic valve. In some embodiments, the second prosthetic valve is a transcatheter heart valve, for example, a balloon expandable or self-expandable transcatheter heart valve. Optionally, the second valve is expanded post-deployment to improve engagement between the first valve and the second valve.
While the invention has been described with reference to particular embodiments, it will be understood that various changes and additional variations may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention or the inventive concept thereof. In addition, many modifications may be made to adapt a particular situation or device to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed herein, but that the invention will include all embodiments falling within the scope of the appended claims.
This application is a continuation of U.S. patent application Ser. No. 29/579,402, filed Sep. 29, 2016, which is a continuation-in-part of U.S. patent application Ser. No. 14/745,287, filed Jun. 19, 2015, now U.S. Pat. No. 9,504,566, which claims the benefit of U.S. Patent Application No. 62/015,290, filed Jun. 20, 2014, the entire contents all of which are expressly incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3143742 | Cromie | Aug 1964 | A |
3320972 | High et al. | May 1967 | A |
3371352 | Siposs et al. | Mar 1968 | A |
3546710 | Shumakov et al. | Dec 1970 | A |
3574865 | Hamaker | Apr 1971 | A |
3755823 | Hancock | Sep 1973 | A |
3839741 | Haller | Oct 1974 | A |
3997923 | Possis | Dec 1976 | A |
4035849 | Angell et al. | Jul 1977 | A |
4078468 | Civitello | Mar 1978 | A |
4079468 | Liotta et al. | Mar 1978 | A |
4084268 | Ionescu et al. | Apr 1978 | A |
4106129 | Carpentier et al. | Aug 1978 | A |
4172295 | Batten | Oct 1979 | A |
4217665 | Bex et al. | Aug 1980 | A |
4218782 | Rygg | Aug 1980 | A |
4259753 | Liotta et al. | Apr 1981 | A |
RE30912 | Hancock | Apr 1982 | E |
4340091 | Skelton et al. | Jul 1982 | A |
4343048 | Ross et al. | Aug 1982 | A |
4364126 | Rosen et al. | Dec 1982 | A |
4388735 | Ionescu et al. | Jun 1983 | A |
4441216 | Ionescu et al. | Apr 1984 | A |
4451936 | Carpentier et al. | Jun 1984 | A |
4470157 | Love | Sep 1984 | A |
4490859 | Black et al. | Jan 1985 | A |
4501030 | Lane | Feb 1985 | A |
4506394 | Bedard | Mar 1985 | A |
4535483 | Klawitter et al. | Aug 1985 | A |
4566465 | Arhan et al. | Jan 1986 | A |
4605407 | Black et al. | Aug 1986 | A |
4626255 | Reichad et al. | Dec 1986 | A |
4629459 | Ionescu et al. | Dec 1986 | A |
4680031 | Alonso | Jul 1987 | A |
4687483 | Fisher et al. | Aug 1987 | A |
4705516 | Barone et al. | Nov 1987 | A |
4725274 | Lane et al. | Feb 1988 | A |
4731074 | Rousseau et al. | Mar 1988 | A |
4778461 | Pietsch et al. | Oct 1988 | A |
4790843 | Carpentier et al. | Dec 1988 | A |
4851000 | Gupta | Jul 1989 | A |
4863470 | Carter | Sep 1989 | A |
4888009 | Lederman et al. | Dec 1989 | A |
4914097 | Oda et al. | Apr 1990 | A |
4960424 | Grooters | Oct 1990 | A |
4993428 | Arms | Feb 1991 | A |
5010892 | Colvin et al. | Apr 1991 | A |
5032128 | Alonso | Jul 1991 | A |
5037434 | Lane | Aug 1991 | A |
5147391 | Lane | Sep 1992 | A |
5163955 | Love et al. | Nov 1992 | A |
5258023 | Reger | Nov 1993 | A |
5316016 | Adams et al. | May 1994 | A |
5326370 | Love et al. | Jul 1994 | A |
5326371 | Love et al. | Jul 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5360014 | Sauter et al. | Nov 1994 | A |
5360444 | Kusuhara | Nov 1994 | A |
5376112 | Duran | Dec 1994 | A |
5396887 | Imran | Mar 1995 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5423887 | Love et al. | Jun 1995 | A |
5425741 | Lemp et al. | Jun 1995 | A |
5431676 | Dubrul et al. | Jul 1995 | A |
5449384 | Johnson | Sep 1995 | A |
5449385 | Religa et al. | Sep 1995 | A |
5469868 | Reger | Nov 1995 | A |
5488789 | Religa et al. | Feb 1996 | A |
5489296 | Love et al. | Feb 1996 | A |
5489297 | Duran | Feb 1996 | A |
5489298 | Love et al. | Feb 1996 | A |
5500016 | Fisher | Mar 1996 | A |
5533515 | Coller et al. | Jul 1996 | A |
5549665 | Vesely et al. | Aug 1996 | A |
5562729 | Purdy et al. | Oct 1996 | A |
5571215 | Sterman et al. | Nov 1996 | A |
5573007 | Bobo, Sr. | Nov 1996 | A |
5578076 | Krueger et al. | Nov 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5618307 | Donlon et al. | Apr 1997 | A |
5626607 | Malecki et al. | May 1997 | A |
5628789 | Vanney et al. | May 1997 | A |
5693090 | Unsworth et al. | Dec 1997 | A |
5695503 | Krueger et al. | Dec 1997 | A |
5713952 | Vanney et al. | Feb 1998 | A |
5716370 | Williamson, IV et al. | Feb 1998 | A |
5728064 | Burns et al. | Mar 1998 | A |
5728151 | Garrison et al. | Mar 1998 | A |
5735894 | Krueger et al. | Apr 1998 | A |
5752522 | Murphy | May 1998 | A |
5755782 | Love et al. | May 1998 | A |
5766240 | Johnson | Jun 1998 | A |
5800527 | Jansen et al. | Sep 1998 | A |
5814097 | Sterman et al. | Sep 1998 | A |
5814098 | Hinnenkamp et al. | Sep 1998 | A |
5824064 | Taheri | Oct 1998 | A |
5824068 | Bugge | Oct 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5855563 | Kaplan et al. | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5855801 | Lin et al. | Jan 1999 | A |
5861028 | Angell | Jan 1999 | A |
5891160 | Williamson, IV et al. | Apr 1999 | A |
5895420 | Mirsch, II et al. | Apr 1999 | A |
5902308 | Murphy | May 1999 | A |
5908450 | Gross et al. | Jun 1999 | A |
5919147 | Jain | Jul 1999 | A |
5921934 | Teo | Jul 1999 | A |
5921935 | Hickey | Jul 1999 | A |
5924984 | Rao | Jul 1999 | A |
5935163 | Gabbay | Aug 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5972004 | Williamson, IV et al. | Oct 1999 | A |
5984959 | Robertson et al. | Nov 1999 | A |
5984973 | Girard et al. | Nov 1999 | A |
6010531 | Donlon et al. | Jan 2000 | A |
6042554 | Rosenman et al. | Mar 2000 | A |
6042607 | Williamson, IV et al. | Mar 2000 | A |
6048362 | Berg | Apr 2000 | A |
6066160 | Colvin et al. | May 2000 | A |
6074418 | Buchanan et al. | Jun 2000 | A |
6081737 | Shah | Jun 2000 | A |
6099475 | Seward et al. | Aug 2000 | A |
6106550 | Magovern et al. | Aug 2000 | A |
6110200 | Hinnenkamp | Aug 2000 | A |
6117091 | Young et al. | Sep 2000 | A |
6126007 | Kari et al. | Oct 2000 | A |
6162233 | Williamson, IV et al. | Dec 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6176877 | Buchanan et al. | Jan 2001 | B1 |
6197054 | Hamblin, Jr. et al. | Mar 2001 | B1 |
6217611 | Klostermeyer | Apr 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6241765 | Griffin et al. | Jun 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6264611 | Ishikawa et al. | Jul 2001 | B1 |
6283127 | Sterman et al. | Sep 2001 | B1 |
6287339 | Vazquez et al. | Sep 2001 | B1 |
6290674 | Roue et al. | Sep 2001 | B1 |
6312447 | Grimes | Nov 2001 | B1 |
6312465 | Griffin et al. | Nov 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6350282 | Eberhardt | Feb 2002 | B1 |
6371983 | Lane | Apr 2002 | B1 |
6375620 | Oser et al. | Apr 2002 | B1 |
6402780 | Williamson, IV et al. | Jun 2002 | B2 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440164 | Di Matteo et al. | Aug 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6468305 | Otte | Oct 2002 | B1 |
6491624 | Lotfi | Dec 2002 | B1 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6582464 | Gabbay | Jun 2003 | B2 |
6585766 | Huynh et al. | Jul 2003 | B1 |
6613087 | Healy et al. | Sep 2003 | B1 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6682559 | Myers et al. | Jan 2004 | B2 |
6685739 | DiMatteo et al. | Feb 2004 | B2 |
6730118 | Spenser et al. | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6764508 | Roehe et al. | Jul 2004 | B1 |
6767362 | Schreck | Jul 2004 | B2 |
6773457 | Ivancev et al. | Aug 2004 | B2 |
6786925 | Schoon et al. | Sep 2004 | B1 |
6790229 | Berreklouw | Sep 2004 | B1 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6805711 | Quijano et al. | Oct 2004 | B2 |
6893459 | Macoviak | May 2005 | B1 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
6939365 | Fogarty et al. | Sep 2005 | B1 |
7011681 | Vesely | Mar 2006 | B2 |
7025780 | Gabbay | Apr 2006 | B2 |
7070616 | Majercak et al. | Jul 2006 | B2 |
7097659 | Woolfson et al. | Aug 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7137184 | Schreck | Nov 2006 | B2 |
7147663 | Berg et al. | Dec 2006 | B1 |
7153324 | Case et al. | Dec 2006 | B2 |
7195641 | Palmaz et al. | Mar 2007 | B2 |
7201771 | Lane | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7238200 | Lee et al. | Jul 2007 | B2 |
7247167 | Gabbay | Jul 2007 | B2 |
7252682 | Seguin | Aug 2007 | B2 |
7261732 | Justino | Aug 2007 | B2 |
7333013 | Berger | Feb 2008 | B2 |
RE40377 | Williamson, IV et al. | Jun 2008 | E |
7422603 | Lane | Sep 2008 | B2 |
7474223 | Nycz et al. | Jan 2009 | B2 |
7513909 | Lane et al. | Apr 2009 | B2 |
7556647 | Drews et al. | Jul 2009 | B2 |
7569072 | Berg et al. | Aug 2009 | B2 |
7998151 | St. Goar et al. | Aug 2011 | B2 |
8075536 | Gray et al. | Dec 2011 | B2 |
8784481 | Alkhatib et al. | Jul 2014 | B2 |
8845720 | Conklin | Sep 2014 | B2 |
8998981 | Tuval et al. | Apr 2015 | B2 |
9089422 | Ryan et al. | Jul 2015 | B2 |
20010039435 | Roue et al. | Nov 2001 | A1 |
20010039436 | Frazier et al. | Nov 2001 | A1 |
20010041914 | Frazier et al. | Nov 2001 | A1 |
20010041915 | Roue et al. | Nov 2001 | A1 |
20010049492 | Frazier et al. | Dec 2001 | A1 |
20020020074 | Love et al. | Feb 2002 | A1 |
20020026238 | Lane et al. | Feb 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020058995 | Stevens | May 2002 | A1 |
20020123802 | Snyders | Sep 2002 | A1 |
20020138138 | Yang | Sep 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020188348 | DiMatteo et al. | Dec 2002 | A1 |
20020198594 | Schreck | Dec 2002 | A1 |
20030014104 | Cribier | Jan 2003 | A1 |
20030023300 | Bailey et al. | Jan 2003 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030036795 | Andersen et al. | Feb 2003 | A1 |
20030040792 | Gabbay | Feb 2003 | A1 |
20030055495 | Pease et al. | Mar 2003 | A1 |
20030055496 | Cal et al. | Mar 2003 | A1 |
20030105519 | Fasol et al. | Jun 2003 | A1 |
20030109924 | Cribier | Jun 2003 | A1 |
20030114913 | Spenser et al. | Jun 2003 | A1 |
20030130729 | Paniagua et al. | Jul 2003 | A1 |
20030149478 | Figulla et al. | Aug 2003 | A1 |
20030167089 | Lane | Sep 2003 | A1 |
20030236568 | Hojeibane et al. | Dec 2003 | A1 |
20040019374 | Hojeibane et al. | Jan 2004 | A1 |
20040034411 | Quijano et al. | Feb 2004 | A1 |
20040044406 | Woolfson et al. | Mar 2004 | A1 |
20040106976 | Bailey et al. | Jun 2004 | A1 |
20040122514 | Fogarty et al. | Jun 2004 | A1 |
20040122516 | Fogarty et al. | Jun 2004 | A1 |
20040167573 | Williamson et al. | Aug 2004 | A1 |
20040167619 | Case et al. | Aug 2004 | A1 |
20040186563 | Lobbi | Sep 2004 | A1 |
20040186565 | Schreck | Sep 2004 | A1 |
20040193261 | Berreklouw | Sep 2004 | A1 |
20040206363 | McCarthy et al. | Oct 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040210307 | Khairkhahan | Oct 2004 | A1 |
20040225355 | Stevens | Nov 2004 | A1 |
20040236411 | Sarac et al. | Nov 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20040260390 | Sarac et al. | Dec 2004 | A1 |
20050010285 | Lambrecht et al. | Jan 2005 | A1 |
20050027348 | Case et al. | Feb 2005 | A1 |
20050033398 | Seguin | Feb 2005 | A1 |
20050043760 | Fogarty et al. | Feb 2005 | A1 |
20050043790 | Seguin | Feb 2005 | A1 |
20050060029 | Le et al. | Mar 2005 | A1 |
20050065594 | DiMatteo et al. | Mar 2005 | A1 |
20050065614 | Stinson | Mar 2005 | A1 |
20050075584 | Cali | Apr 2005 | A1 |
20050075713 | Biancucci et al. | Apr 2005 | A1 |
20050075717 | Nguyen et al. | Apr 2005 | A1 |
20050075718 | Nguyen et al. | Apr 2005 | A1 |
20050075719 | Bergheim | Apr 2005 | A1 |
20050075720 | Nguyen et al. | Apr 2005 | A1 |
20050075724 | Svanidze et al. | Apr 2005 | A1 |
20050080454 | Drews et al. | Apr 2005 | A1 |
20050096738 | Cali et al. | May 2005 | A1 |
20050137682 | Justino | Jun 2005 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137692 | Haug et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050159811 | Lane | Jul 2005 | A1 |
20050165479 | Drews et al. | Jul 2005 | A1 |
20050182486 | Gabbay | Aug 2005 | A1 |
20050192665 | Spenser et al. | Sep 2005 | A1 |
20050203616 | Cribier | Sep 2005 | A1 |
20050203617 | Forster et al. | Sep 2005 | A1 |
20050203618 | Sharkawy et al. | Sep 2005 | A1 |
20050216079 | MaCoviak | Sep 2005 | A1 |
20050222674 | Paine | Oct 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20050240263 | Fogarty et al. | Oct 2005 | A1 |
20050251252 | Stobie | Nov 2005 | A1 |
20050261765 | Liddicoat | Nov 2005 | A1 |
20050283231 | Haug et al. | Dec 2005 | A1 |
20060008497 | Gabbay | Jan 2006 | A1 |
20060025857 | Bergheim et al. | Feb 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060058871 | Zakay et al. | Mar 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060085060 | Campbell | Apr 2006 | A1 |
20060095125 | Chinn et al. | May 2006 | A1 |
20060122634 | Ino et al. | Jun 2006 | A1 |
20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
20060154230 | Cunanan et al. | Jul 2006 | A1 |
20060167543 | Bailey et al. | Jul 2006 | A1 |
20060195184 | Lane et al. | Aug 2006 | A1 |
20060195185 | Lane et al. | Aug 2006 | A1 |
20060195186 | Drews et al. | Aug 2006 | A1 |
20060207031 | Cunanan et al. | Sep 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060271172 | Tehrani | Nov 2006 | A1 |
20060271175 | Woolfson et al. | Nov 2006 | A1 |
20060276813 | Greenberg | Dec 2006 | A1 |
20060287717 | Rowe et al. | Dec 2006 | A1 |
20060287719 | Rowe et al. | Dec 2006 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070016285 | Lane et al. | Jan 2007 | A1 |
20070016286 | Herrmann et al. | Jan 2007 | A1 |
20070016288 | Gurskis et al. | Jan 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070078509 | Lotfy | Apr 2007 | A1 |
20070078510 | Ryan | Apr 2007 | A1 |
20070100440 | Figulla et al. | May 2007 | A1 |
20070129794 | Realyvasquez | Jun 2007 | A1 |
20070142906 | Figulla et al. | Jun 2007 | A1 |
20070142907 | Moaddeb et al. | Jun 2007 | A1 |
20070150053 | Gurskis et al. | Jun 2007 | A1 |
20070156233 | Kapadia et al. | Jul 2007 | A1 |
20070162103 | Case et al. | Jul 2007 | A1 |
20070162107 | Haug et al. | Jul 2007 | A1 |
20070162111 | Fukamachi et al. | Jul 2007 | A1 |
20070179604 | Lane | Aug 2007 | A1 |
20070185565 | Schwammenthal et al. | Aug 2007 | A1 |
20070198097 | Zegdi | Aug 2007 | A1 |
20070203575 | Forster et al. | Aug 2007 | A1 |
20070203576 | Lee et al. | Aug 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070225801 | Drews et al. | Sep 2007 | A1 |
20070233237 | Krivoruchko | Oct 2007 | A1 |
20070238979 | Huynh et al. | Oct 2007 | A1 |
20070239266 | Birdsall | Oct 2007 | A1 |
20070239269 | Dolan et al. | Oct 2007 | A1 |
20070239273 | Allen | Oct 2007 | A1 |
20070255398 | Yang et al. | Nov 2007 | A1 |
20070260305 | Drews et al. | Nov 2007 | A1 |
20070265701 | Gurskis et al. | Nov 2007 | A1 |
20070270944 | Bergheim et al. | Nov 2007 | A1 |
20070282436 | Pinchuk | Dec 2007 | A1 |
20070288089 | Gurskis et al. | Dec 2007 | A1 |
20080033543 | Gurskis et al. | Feb 2008 | A1 |
20080039934 | Styrc | Feb 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080119875 | Ino et al. | May 2008 | A1 |
20080154356 | Obermiller et al. | Jun 2008 | A1 |
20080228263 | Ryan | Sep 2008 | A1 |
20080319543 | Lane | Dec 2008 | A1 |
20090036903 | Ino et al. | Feb 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090156928 | Evans et al. | Jun 2009 | A1 |
20090192591 | Ryan et al. | Jul 2009 | A1 |
20090192599 | Lane et al. | Jul 2009 | A1 |
20090264989 | Bonhoeffer et al. | Oct 2009 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100168839 | Braido et al. | Jul 2010 | A1 |
20100185277 | Braido et al. | Jul 2010 | A1 |
20100249923 | Alkhatib et al. | Sep 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20110034802 | Shrivastava et al. | Feb 2011 | A1 |
20120065503 | Rogers et al. | Mar 2012 | A1 |
20140163673 | Bruchman et al. | Jun 2014 | A1 |
20140343670 | Bakis et al. | Nov 2014 | A1 |
20150018944 | O'Connell et al. | Jan 2015 | A1 |
20160296324 | Bapat et al. | Oct 2016 | A1 |
20180021554 | Nebosky et al. | Jan 2018 | A1 |
Number | Date | Country |
---|---|---|
0125393 | Nov 1984 | EP |
0143246 | Jun 1985 | EP |
1239795 | Dec 2006 | EP |
H1189940 | Apr 1999 | JP |
1116573 | Jul 1985 | SU |
1697790 | Dec 1991 | SU |
9213502 | Aug 1992 | WO |
9742871 | Nov 1997 | WO |
2009106545 | Sep 2009 | WO |
2010019781 | Feb 2010 | WO |
2012018779 | Feb 2012 | WO |
Entry |
---|
International Search Report from corresponding PCT case No. PCT/US2015/036806 dated Oct. 1, 2015. |
Japanese Office Action for Appl No. 2016-533519 dated Dec. 19, 2016. |
Bapat, et al., “Fluoroscopic Guide to an Ideal Implant Position for Sapien XT and CoreValve During a Valve-in-Valve Procedure”, Cardiovascular Interventions, vol. 6, No. 11, 2013, Published by Elsevier Inc., London, United Kindgom, 9 pages. |
Number | Date | Country | |
---|---|---|---|
20190167422 A1 | Jun 2019 | US |
Number | Date | Country | |
---|---|---|---|
62015290 | Jun 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 29579402 | Sep 2016 | US |
Child | 16270849 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14745287 | Jun 2015 | US |
Child | 29579402 | US |